|
|
||||||||
From the Department of Microbiology, University of Mississippi Medical Center, Jackson, Mississippi.
PURPOSE.
-Toxin mediates extreme corneal damage during Staphylococcus aureus keratitis. Chemical inhibition of this toxin was sought to provide relief from toxin-mediated pathology.
METHODS. Inhibition of
-toxin by phosphate-buffered saline (PBS), 0.1% methyl-β-cyclodextrin (CD), or CD plus cholesterol (0.1%, CD-cholesterol) was assayed by hemolysis of rabbit erythrocytes. Pathologic changes in rabbit corneas injected with 12 hemolytic units of
-toxin suspended in PBS, 1% CD, or 1% CD-cholesterol were compared over time. Rabbit corneas injected with 102 colony forming units (CFU) of S. aureus were treated from 7 to 13 hours postinfection (PI) with a total of 15 drops of CD-cholesterol, CD, or PBS. Slit lamp examination (SLE) and measurement of erosions were performed at 13 hours PI and bacteria were quantified at 14 hours PI.
RESULTS. Toxin-mediated lysis of erythrocytes was inhibited up to 16,000-fold in the presence of CD-cholesterol compared with CD or PBS. Eyes injected with
-toxin mixed with CD-cholesterol had, at 7 hours postinjection, significantly smaller erosions than eyes injected with
-toxin in PBS or
-toxin mixed with CD (P = 0.0090 and P = 0.0035, respectively). Eyes infected with S. aureus and treated with CD-cholesterol had significantly lower SLE scores than eyes treated with CD or PBS (P
0.0103 and P
0.0017, respectively); however, there were no differences in the number of bacteria present (P
0.0648).
CONCLUSIONS. CD-cholesterol is a potent inhibitor of
-toxin activity in vitro and an effective means to arrest corneal damage during S. aureus keratitis.
This article has been cited by other articles:
![]() |
B. E. Ragle, V. A. Karginov, and J. Bubeck Wardenburg Prevention and Treatment of Staphylococcus aureus Pneumonia with a {beta}-Cyclodextrin Derivative Antimicrob. Agents Chemother., January 1, 2010; 54(1): 298 - 304. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |